Lucid Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid, the Company), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today provided a business update for the Company and presented preliminary financial results for the three and six months ended June 30, 2022.
- Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid, the Company), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today provided a business update for the Company and presented preliminary financial results for the three and six months ended June 30, 2022.
- A conference call and webcast for todays business update and second quarter 2022 financial results will take place at 4:30 PM EDT.
- The laboratory processed 850 commercial EsoGuard tests in the second quarter of 2022, which represents a 60% increase sequentially from the first quarter of 2022 and an over 300% increase annually from the second quarter of 2021.
- To supplement our unaudited financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Companys financial results.